- Conditions
- Asthma, Bronchoconstriction
- Interventions
- Levalbuterol HFA MDI, Racemic Albuterol
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Signal Hill, California • Denver, Colorado + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 219
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline, Placebo Comparator
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • National City, California • Paramount, California + 37 more
- Conditions
- Bipolar Depression
- Interventions
- lurasidone
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 817 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 58
- States / cities
- Little Rock, Arkansas • Anaheim, California • Chino, California + 49 more
- Conditions
- Autism
- Interventions
- Lurasidone 20 mg daily, Lurasidone, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 41
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Newport Beach, California + 38 more
- Conditions
- Schizophrenia
- Interventions
- Lurasidone 20 mg, Lurasidone 40 mg, Lurasidone 80mg
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Cerritos, California • Garden Grove, California + 21 more
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Alvocidib (flavopiridol) and cytarabine (Ara-C), Alvocidib (flavopiridol)
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 18
- States / cities
- Clovis, California • Duarte, California • Los Angeles, California + 14 more
- Conditions
- Bipolar I Disorder
- Interventions
- Lurasidone
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 25
- States / cities
- Dothan, Alabama • Glendale, California • Los Angeles, California + 22 more
- Conditions
- Advanced Solid Tumors
- Interventions
- TP-0184
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Kansas City, Kansas + 2 more
- Conditions
- Primary Insomnia
- Interventions
- Eszopiclone, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Interventions
- arformoterol tartrate inhalation solution, Salmeterol, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 741 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 65
- States / cities
- Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
- Conditions
- Menopause, Insomnia
- Interventions
- Eszopiclone, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Overactive Bladder Syndrome (OABS)
- Interventions
- Placebo, SMP-986
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 21
- States / cities
- Tuscon, Arizona • Atherton, California • San Bernadino, California + 18 more
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Eszopiclone, Placebo control
- Drug
- Lead sponsor
- Walter Reed Army Medical Center
- Federal
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Allergic Rhinitis, Perennial Allergic Rhinitis
- Interventions
- Ciclesonide HFA 80 mcg, Ciclesonide HFA 160 mcg, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 45
- States / cities
- Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 36 more
- Conditions
- Allergic Rhinitis
- Interventions
- placebo, isotonic ciclesonide, hypotonic ciclesonide
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Myelodysplastic Syndromes (MDS)
- Interventions
- Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
- Combination Product
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 9 more
- Conditions
- Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer, Colorectal Carcinoma, Recurrent Ovarian Carcinoma, BRAF-Mutated Melanoma
- Interventions
- TP-0903
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Denver, Colorado + 12 more
- Conditions
- Myelofibrosis
- Interventions
- Nusivertib, Ruxolitinib, Momelotinib
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Duarte, California + 25 more
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Contrast Agent, Leuprolide, Magnetic Resonance Imaging, Physical Performance Testing, Relugolix
- Procedure · Other · Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Venetoclax, Alvocidib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 5 more
- Conditions
- Perennial Allergic Rhinitis, PAR
- Interventions
- Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 848 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 60
- States / cities
- Hot Springs, Arkansas • Little Rock, Arkansas • Costa Mesa, California + 51 more
- Conditions
- Parkinson Disease, Off Episodes
- Interventions
- APL-130277, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
- Conditions
- Healthy
- Interventions
- eszopiclone, zolpidem, placebo
- Drug
- Lead sponsor
- Kettering Health Network
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- Kettering, Ohio
- Conditions
- Neurogenic Detrusor Overactivity
- Interventions
- Vibegron
- Drug
- Lead sponsor
- Urovant Sciences GmbH
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Orange, California • Aurora, Colorado + 8 more